{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:45:16Z","timestamp":1781700316831,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejps.2021.106097","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T13:36:45Z","timestamp":1639316205000},"page":"106097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum"],"prefix":"10.1016","volume":"169","author":[{"given":"Lis Marie","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Jos\u00e9","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Lima Barros","family":"de Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Keiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edite","family":"Kanashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raissa H.","family":"de Araujo Eliodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mussya","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera L\u00facia Teixeira","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Fotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e1dia Araci","family":"Bou-Chacra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.106097_bib0032","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1021\/acs.jpcb.5b11448","article-title":"Properties of poloxamer molecules and poloxamer micelles dissolved in water and next to lipid bilayers: results from computer simulations","volume":"120","author":"Adhikari","year":"2016","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejps.2021.106097_bib0014","first-page":"34","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"10.1016\/j.ejps.2021.106097_bib0033","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2021.106097_bib0002","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.ejps.2021.106097_bib0003","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijantimicag.2012.01.003","article-title":"In vitro evaluation of bisnaphthalimidopropyl derivatives loaded into pegylated nanoparticles against Leishmania infantum protozoa","volume":"39","author":"Costa Lima","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2021.106097_bib0043","article-title":"Nanoliposomal buparvaquone immunomodulates leishmania infantum-infected macrophages and is highly effective in a murine model","volume":"61","author":"Costa-Silva","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2021.106097_bib0004","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/30.6.827","article-title":"The activity of hydroxynaphthoquinones against Leishmania donovani","author":"Croft","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2021.106097_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2012.05.010","article-title":"Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?","volume":"47","author":"Das","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106097_bib0029","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/22\/27\/275102","article-title":"Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50\/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery","volume":"22","author":"Date","year":"2011","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejps.2021.106097_bib0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12249-018-1272-0","article-title":"Drug-lipid conjugates for enhanced oral drug delivery","volume":"20","author":"Date","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2021.106097_bib0009","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijpharm.2018.06.018","article-title":"Promising nanotherapy in treating leishmaniasis","volume":"547","author":"de Souza","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106097_bib0051","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.00014-08","article-title":"Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients","volume":"52","author":"Dorlo","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2021.106097_bib0050","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2021.106097_bib0052","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/jac\/dks273","article-title":"Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis","volume":"67","author":"Fortin","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2021.106097_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.106097_bib0001","series-title":"Global Leishmaniasis Update, 2006\u20132015: a Turning Point In Leishmaniasis Surveillance","first-page":"557","year":"2017"},{"key":"10.1016\/j.ejps.2021.106097_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00707-15","article-title":"In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model","volume":"59","author":"Hendrickx","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2021.106097_bib0038","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1208\/pt050345","article-title":"Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note","volume":"5","author":"Jain","year":"2004","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2021.106097_bib0021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-4939-9210-2_17","article-title":"Syrian hamster as na advanced experimental model for visceral leishmaniasis","volume":"1971","author":"Jim\u00e9nez-Ant\u00f3n","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejps.2021.106097_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14227\/DT210114P45","article-title":"A Simple, Safe, and Environmentally Friendly Method of FaSSIF and FeSSIF Preparation Without Methylene Chloride","author":"Jogia","year":"2014","journal-title":"Dissolut. Technol."},{"key":"10.1016\/j.ejps.2021.106097_bib0011","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2174\/092986712799828300","article-title":"Leishmaniasis: prevention, parasite detection and treatment","volume":"19","author":"Kobets","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejps.2021.106097_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.drudis.2018.09.023","article-title":"Application of nanotechnology to improve the therapeutic benefits of statins","volume":"24","author":"Korani","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2021.106097_bib0040","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1053\/j.gastro.2015.10.025","article-title":"Next Generation of Pancreatic Enzyme Replacement Therapy: recombinant Microbial Enzymes and Finding the Perfect Lipase","volume":"149","author":"Lowe","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2021.106097_bib0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/microorganisms7120695","article-title":"Protective or detrimental? Understanding the role of host immunity in leishmaniasis","volume":"7","author":"Meira","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejps.2021.106097_bib0023","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response","volume":"166","author":"Melby","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejps.2021.106097_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005924","article-title":"New insights into experimental visceral leishmaniasis: real-time in vivo imaging of Leishmania donovani virulence","volume":"11","author":"Melo","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejps.2021.106097_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.actatropica.2011.05.012","article-title":"Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human","volume":"119","author":"Michel","year":"2011","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejps.2021.106097_bib0036","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1039\/C3FO60702J","article-title":"A standardised static in vitro digestion method suitable for food - an international consensus","volume":"5","author":"Minekus","year":"2014","journal-title":"Food Funct."},{"key":"10.1016\/j.ejps.2021.106097_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9781603","article-title":"Buparvaquone Nanostructured Lipid Carrier: development of an Affordable Delivery System for the Treatment of Leishmaniases","author":"Monteiro","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ejps.2021.106097_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijantimicag.2017.01.033","article-title":"Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system","volume":"50","author":"Monteiro","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2021.106097_bib0044","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2613.2001.00199.x","article-title":"Tissue granuloma structure-function in experimental visceral leishmaniasis","volume":"82","author":"Murray","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.ejps.2021.106097_bib0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.foodchem.2017.01.015","article-title":"Development of nanostructured lipid carriers for the encapsulation and controlled release of vitamin D3","volume":"225","author":"Park","year":"2017","journal-title":"Food Chem."},{"key":"10.1016\/j.ejps.2021.106097_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.exppara.2012.01.010","article-title":"Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi","volume":"130","author":"Reim\u00e3o","year":"2012","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejps.2021.106097_bib0047","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/17460441.2020.1743674","article-title":"The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history","volume":"15","author":"Reim\u00e3o","year":"2020","journal-title":"Exp. Opin. Drug Discov."},{"key":"10.1016\/j.ejps.2021.106097_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118624","article-title":"Tacrolimus-loaded lecithin-based nanostructured lipid carrier and nanoemulsion with propylene glycol monocaprylate as a liquid lipid: formulation characterization and assessment of dermal delivery compared to referent ointment","volume":"569","author":"Savi\u0107","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106097_bib0016","first-page":"1","article-title":"Development of mebendazole loaded nanostructured lipid carriers for lymphatic targeting: optimization, characterization, in-vitro and in-vivo evalutation","volume":"39","author":"Shrivastava","year":"2020","journal-title":"Part. Sci. Technol."},{"key":"10.1016\/j.ejps.2021.106097_bib0006","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acs.molpharmaceut.8b00097","article-title":"Orally bioavailable and effective buparvaquone lipid-based nanomedicines for visceral leishmaniasis","volume":"15","author":"Smith","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2021.106097_bib0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17425247.2020.1727883","article-title":"SLN and NLC for topical, dermal, and transdermal drug delivery","volume":"17","author":"Souto","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2021.106097_bib0034","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12551-016-0218-6","article-title":"Dynamic light scattering: a practical guide and applications in biomedical sciences","volume":"8","author":"Stetefeld","year":"2016","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ejps.2021.106097_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine \u2013 a life-saving drug for leishmaniasis \u2013 is unavailable to people who need it the most","volume":"3","author":"Sunyoto","year":"2018","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.ejps.2021.106097_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejpb.2016.10.023","article-title":"The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN)","volume":"110","author":"Sznitowska","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.106097_bib0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2008.02.011","article-title":"Junyaprasert, V. B. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC","volume":"128","author":"Teeranachaideekul","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.106097_bib0042","doi-asserted-by":"crossref","unstructured":"Thapa, R., Mondal, S., Riikonen, J., Rantanen, J., N\u00e4kki, S., Nissinen, T., N\u00e4rv\u00e4nen, A., Lehto, V.P., 2021. Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. PLoS Negl. Trop. Dis.. 15, e0009533. https:\/\/doi.org\/10.1371\/journal.pntd.0009533.","DOI":"10.1371\/journal.pntd.0009533"},{"key":"10.1016\/j.ejps.2021.106097_bib0048","doi-asserted-by":"crossref","first-page":"770","DOI":"10.4269\/ajtmh.14-0787","article-title":"Lymphatic dissemination in cutaneous leishmaniasis following local treatment","volume":"93","author":"Thomaidou","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejps.2021.106097_bib0037","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.carbpol.2014.06.070","article-title":"Interactions between cellulose ethers and a bile salt in the control of lipid digestion of lipid-based systems","volume":"113","author":"Torcello-G\u00f3mez","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejps.2021.106097_bib0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/pharmaceutics11030132","article-title":"Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs","volume":"11","author":"Tran","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106097_bib0019","year":"2019","journal-title":"USP, Dissolution Methods Database"},{"key":"10.1016\/j.ejps.2021.106097_bib0039","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/02652048.2015.1094532","article-title":"Modification of solid lipid nanoparticles loaded with nebivolol hydrochloride for improvement of oral bioavailability in treatment of hypertension: polyethylene glycol versus chitosan oligosaccharide lactate","volume":"33","author":"\u00dcst\u00fcnda\u011f-Okur","year":"2016","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2021.106097_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-4017(96)01150-8","article-title":"Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis","volume":"77","author":"Vexenat","year":"1998","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.ejps.2021.106097_bib0049","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1208\/s12249-019-1293-3","article-title":"Lipid-Based Nanocarriers for Lymphatic Transportation","volume":"20","author":"Vishwakarma","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2021.106097_bib0026","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcis.2017.07.008","article-title":"Effect of surfactant concentration and solidification temperature on the characteristics and stability of nanostructured lipid carrier (NLC) prepared from rambutan (Nephelium lappaceum L.) kernel fat","volume":"505","author":"Witayaudom","year":"2017","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejps.2021.106097_bib0031","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.93.028101","article-title":"Lipid corralling and poloxamer squeeze-out in membranes","volume":"93","author":"Wu","year":"2004","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.ejps.2021.106097_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejpb.2016.10.021","article-title":"110. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery","volume":"110","author":"Zoubari","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721003985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:01:06Z","timestamp":1760529666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721003985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":53,"alternative-id":["S0928098721003985"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106097","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106097"}}